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Summary 
Pemphigus vulgaris (PV) is an autoimmune disease caused by high concentrations of antibody 
to an epidermal cadherin. The disease is associated with two kinds of HLA-DR4, DQ8 haplotypes 
dominantly distributed among Jewish patients, and these plus DR6, DQ5 haplotypes in non- 
Jewish patients. Low levels of the PV antibody were found in 48% of a total of 120 asymptomatic 
parents, children, and siblings of 31 patients, thus exhibiting dominant inheritance. The inheritance 
of these low levels of antibody in asymptomatic  relatives was linked to the major histocompatibihty 
complex with a highly significant logarithm of the odds score of 9.07,  almost always to a DR4 
or DR6 haplotype of the patient. Disease appears to occur in susceptible individuals with low 
levels of antibody when a second factor, either environmental or genetic, induces high levels, 
sufficient  to produce blisters. 
I 
n contrast to diseases like sickle cell anemia, where all ge- 
neticaUy susceptible individuals have the disease and carriers 
are easily detected, the genetics of autoimmune diseases are 
far less clear. Although many autoimmune  diseases show MHC 
associations, genetically susceptible persons may not have the 
disease and carriers are usually not detectable. This phenom- 
enon has been called incomplete penetrance. Another problem 
is extensive linkage disequilibrium within the human MHC. 
In our experience, and that of others, many MHC-associated 
diseases are marked by fixed or extended haplotypes with con- 
served DNA in independent examples, over at least the HLA- 
B-DR, DQ interval,  that form the basis of the linkage dise- 
quilibrium, making localization of a specific susceptibility 
gene particularly difficult (1). 
Our previous studies demonstrated that in patients with 
the rare autoimmune blistering skin disease pemphigus vul- 
garis (PV), 1 caused by an antibody to a skin cadherin (2-4), 
three conserved or extended MHC haplotypes or their class 
II segments are disease associated (5, 6). We found that sus- 
ceptibility in Ashkenazi Jewish patients was associated with 
the extended haplotype [HLA-B38, SC21, DtL4, DQ8], and 
the possible extended haplotype HLA-B35, SC31, DR4, DQ8, 
or (unusually) DR4, DQ8-containing segments of these haplo- 
1 Abbreviation  used in this paper: PV, pemphigus  vulgaris. 
types with a variety of other HLA-B and complotype markers. 
These findings helped explain the DR4 increase (7) and the 
DR4, DQ8 association  among Jewish PV patients (8). Of 
non-Jewish PV patients (6), some had HLA-DR4, DQ8 haplo- 
types, as in the Jewish patients, but also, consistent with the 
known increase in HLA-B55(22)  (9) and HLA-DK6, DQ1 
(10), many had HLA-B55, SB45, DK14(6),  DQ5(1) or its 
presumed DR14,  DQ5  segment. 
Clues to the mode of inheritance of these disorders are the 
distribution of MHC alleles in populations (11) or among 
multiple affected siblings (12). Thus, the inheritance of MHC- 
associated susceptibility to type I diabetes is essentially reces- 
sive (13, 14), whereas  that  for  ankylosing spondylitis is 
dominant (11). From the analysis of the distribution of DR4, 
DQ8 on MHC haplotypes among Jewish patients with PV, 
we inferred that the MHC susceptibility gene operated in 
a dominant fashion  (5). 
If there is a dominantly expressed gene specifying autoan- 
tibody production in PV patients, autoantibody might also 
be present, although at low levels, insufficient to cause symp- 
toms, in relatives of patients who share the susceptibility haplo- 
type. Furthermore, a fraction of normal persons from such 
populations who carry one of these haplotypes might also 
have the PV antibody. 
In the present study, we have approached the problem 
directly and tested the serum of close relatives of PV patients 
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developed sensitive Western blotting  procedure.  We found 
that about half of the healthy immediate relatives of patients 
carry low levels of this antibody and that the presence of an- 
tibody is genetically linked to one of the HLA-DR4 or DR6 
haplotypes,  the  same as occur  in  patients. 
Materials  and Methods 
We studied  174 members of 31  families  of patients with PV. 
The criteria for diagnosis and MHC types of most of these were 
published earlier (5, 6). For the present study, serum was obtained 
from clotted venous blood by centrifugation and analyzed for anti- 
body to skin epithelial surface antigens. 
Serological typing of PBL for HLA-A, B, C, DR, and DQ was 
by microlymphocytotoxicity (15). Fresh frozen EDTA plasma was 
used to type the MHC-encoded complement proteins C4 (16), BF 
(17), and C2 (18). Complotypes are given as BF, C2, C4A, C4B 
types, for example, SC31  is BF*S, C2"C, C4A'3,  C4B'I. 
Serum samples from the study and control subjects were tested 
for antibody to the 130-kD (keratinocytes)  (4) and 105-kD (COLO 
16 tumor cell line) (19) antigens characteristic of PV by a Western 
blot method (20). Immunoblots were produced by incubating sub- 
ject serum with detergent-solubilized normal skin cells or squa- 
mous carcinoma cells after electrophoresis in polyacrylamide gel 
in the presence of SDS. Two modifications of the method described 
previously (20) were introduced to increase sensitivity.  Cell extracts 
were passed through a Sepharose 4B column previously coupled 
to normal human serum to avoid nonspecific binding by serum 
proteins and transferred after electrophoresis to PVDF membranes 
(Bio-Rad Laboratories, Richmond, CA). The membranes were over- 
laid with an IBI enzygraphic web (Eastman Kodak, New Haven, 
CT) to detect bound antibody by the peroxidase reaction. Immu- 
noblots were performed and interpreted blindly.  PV antibody levels 
were estimated in all available members of 10 families by 1:5 and 
then  doubling  dilution,  and  the  titer  was  assigned  as  the  last 
immunoblot-positive dilution. 
Sera from 74 control healthy individuals  who carried [HLA-B38, 
SC21, DR4] (n  =  8); HLA-B35, SC31, DR4 (n  =  10); DI{4 in 
general (n  =  21); HLA-B55, SB45, DR6 (n =  10); DR6 in general 
(n =  2); or none of these markers (n =  23) were studied by immu- 
noblot in addition to 29 spouses of patients for a total of 103 con- 
trol subjects. 
Serum samples were also tested for PV antibody by immunoflu- 
orescence using rhesus monkey esophagus as substrate (2). By im- 
munofluorescence, 30 of 31 patient samples were positive. Of 29 
spouses of patients or carriers of antibody, three (10%) were posi- 
tive for the autoantibody by immunoblot and 2 of 13 (15%) by 
immunofluorescence (one of these was also positive by immuno- 
blot). Only 7 of 62 (11%) of first-degree relatives' sera were posi- 
tive by immunofluorescence, but, of these, six were positive by im- 
munoblot. This, coupled with the negativity of one patient sample 
by this technique,  suggested that immunofluorescence, although 
useful for detecting the high levels of antibody in PV patient sera, 
was not sensitive enough to regularly detect low levels of antibody 
in relatives. On blind specific testing of patients' sera diluted seri- 
ally, it appeared that samples with titers below ",,700 were some- 
times  negative  and  below  200  were  usually  negative  by  im- 
munofluorescence.  Thus,  immunofluorescence  was one  to  two 
orders of magnitude less sensitive than the immunoblot assay. There- 
fore, the presence or absence of PV antibody was assigned by im- 
munoblot. 
To determine formally whether the presence of the antibody was 
MHC linked,  linkage analysis  (21) was carried out between the 
presence of antibody detected by immunoblot and the MHC. One 
family, with two antibody-positive spouses,  was considered to be 
uninformative for linkage. If a patient was heterozygous for HLA- 
DR4 or DR6 and some other HLA-DR., the assumption was made 
that the antibody was linked to the DR4 or DR6 haplotype and 
the family was treated as phase known. Families of patients homozy- 
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Figure  1.  Four families with a proband with PV (filled  symbols). Males are shown as squares, females as circles. The two MHC haplotypes of each 
person and the presence (positive) or absence (negative) of PV antibody are shown below each symbol. The haplotypes linked to the presence of antibody 
are shown in bold. To the right  of each family are shown the immunoblots  for PV antibody. 
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Figure 2.  A plot of the cumulative LOD scores in the 30 informative 
families at recombination fractions from 0 to 0.45. It is clear that the max- 
imal LOD score is a little over 9  at an apparent recombination fraction 
of 0.15-0.20. 
gous for  HLA-DR4  or DR6  or DR4/DR6  heterozygotes were 
analyzed by standard linkage analysis. 
Results 
All patients (31/31) had PV antibody by immunoblot, as 
expected. Of serum samples from 120 parents, children, and 
siblings of patients,  58 or 48%  were positive by immuno- 
blot, very close to the 50%  expected for autosomal domi- 
nant inheritance of the PV antibody. Patient's antibody titers 
ranged from 640 to 5,120 (arithmetic mean, 1,728), whereas 
relatives' antibody titers ranged from 10 to 80 with a mean 
of 20. 
Fig.  1 shows the inheritance  pattern of PV antibody in 
four illustrative families. In family 1757 (Fig. 1 A), it is seen 
that of the patient's immediate relatives, her mother, and one 
of her two children were positive for the PV antibody. These 
individuals shared the MHC haplotype HLA-A26, B35, SC31, 
DR4 with the patient. Her other relatives, who did not share 
this haplotype,  were also antibody negative. Thus, in this 
family, there were four informative meioses and no recom- 
binants. Similarly, in family 1770 (Fig. 1 B), there was linkage 
between the antibody and HLA-B55, SB45, DR6 with no 
recombination. Family 2006 (Fig. 1 C) shows linkage without 
recombination between the antibody and HLA-A1, B38, SC21, 
DR4. On the other hand, in family 2014 (Fig. 1 D), although 
individual  I-1 appears to have transmitted the antibody in 
linkage with the putative susceptibility haplotype HLA-A2, 
B55, SB45, DR6 to the patient II-2, his sisters (II-3 and II-4) 
received the haplotype but did not have the antibody and 
were thus apparent recombinants. His two children (III-2 and 
III-3) were nonrecombinants who received the nonsuscepti- 
bility haplotype A28, B51, FC30, DP,5 and did not have an- 
tibody.  His third child (III-1), on the other hand, received 
the same haplotype but unexpectedly had the antibody and 
was thus a recombinant. 
Of 117 informative meioses in all informative families, 100 
were nonrecombinant for the presence of PV antibody and 
the MHC, and 17 (14.5%) were recombinant. In six of the 
subjects with the latter,  the antibody was present but not 
the linked patient  haplotype,  although four of the six had 
a nonpatient DR4 or DR6 haplotype. In the 11 remaining 
subjects with recombination, the patient haplotype was present 
but no PV antibody was detected. There was no clear age- 
related difference with reference to failure to have antibody 
despite the presence of the patient's  putative  susceptibility 
haplotype. One of eight such parents (12.5%),  3 of 15 sibs 
(20.0%), 6 of 33 children (18.2%),  and one of five (20%) 
grandchildren  of patients  were of this  kind. 
On formal testing (Fig. 2) of all informative families for 
linkage, the maximum logarithm of the odds (LOD) score 
for linkage between the presence of antibody and the MHC 
was 9.07 (highly significant). The most likely recombina- 
tion fraction,  or maximal 0, was 0.15-0.20. 
Table 1 gives the haplotypes clearly segregating with the 
presence of antibody in each of 30 families with a PV pa- 
tient. These are virtually exclusively those with HLA-DP,4, 
DQ8 and DP,6,  DQ5 that were assumed earlier to be the 
dominantly expressed susceptibility haplotypes (5, 6). There 
were four exceptions. Patients 1699 and 1727 carried SC31, 
HLA-DR4, DQ8 haplotypes on their other chromosomes, 
and  patient  1689 carried  HLA-B55,  SB45, DP,6,  DQ5, 
making the identification of the susceptibility haplotype am- 
biguous from class II genes or extended haplotypes  alone. 
Only in patient  1749, in whom the antibody-linked haplo- 
type was with DR5 and the guessed susceptibility haplotype 
was HLA-A26, B35, SC31, DP,4, DQ8, was the guess truly 
incorrect. All the other 24 patient's haplotypes were correctly 
guessed, and the haplotypes in common listed here are the 
same as shown previously (5,  6). 
Of 29 spouses of  patients or carriers of antibody, three (10%) 
were positive for the autoantibody by immunoblot. One of 
these was a 91-yr-old man with myasthenia gravis, a condi- 
tion known to be associated in some patients with the pres- 
ence of PV antibody (22), and two were in family 1797. Of the 
latter, one carried HLA-B35, SC31, DR4, and the other car- 
ried [HLA-B38, SC21, DR4]. Serum from the latter was also 
positive for the pemphigus antibody by immunofluorescence 
assay, as was that of another spouse with no DP-,4 or DR6 
haplotype in family 1719. These results suggested that some 
normal individuals with these haplotypes (and even perhaps 
some without the haplotypes) but no family history of PV 
might carry low levels of the PV antibody. However, of the 
remaining 74 serum samples, including seven with [HLA- 
B38, SC21, DR4] and nine with HLA-B35, SC31, DP,4 from 
healthy controls,  none were positive by immunoblot. 
Discussion 
In autoimmune diseases characterized by autoantibodies, 
several genetic factors, including the MHC, in addition to 
environmental  factors, may be important in pathogenesis. 
However, since the methods for detection of autoantibodies 
have been neither very sensitive nor highly specific, it had 
not been possible to study the genetics of autoantibodies and 
their relationship to the MHC. We have used a very sensitive 
and specific Western blot assay that can detect 10-100 pg of 
the anticadherin (pemphigus) autoantibody. By these means, 
421  Ahmed et al. Table  1.  MHC HapIotypes Linked to Autoantibody in Families 
Jewish  families  Non-Jewish  families 
HLA  HLA  HLA  HLA 
Family  Family 
no.  A  B  Comp.  DR  DQ  no.  A  B  Comp.  DR  DQ 
1799  1  58  SC21  4  8  1770  1  55  SB45  6  5 
1716  2  27  SC21  4  8  2014  2  55  SB45  6  5 
2006  1  38  SC21  4  8  1696  30  55  SB45  6  5 
1789  26  38  SC21  4  8  2016  26  38  SC21  6  5 
1778  26  38  SC21  4  8  1774  24  49  SC01  6  5 
2005  26  38  SC21  4  8  1739  1  8  FC31  6  5 
2370  26  38  SC21  4  8  1945  24  51  SC43  6  5 
1906  26  38  SC21  4  8  1727"  2  37  FC31  6  5 
1807  26  38  SC21  4  8  1740  2  44  SC30  6  5 
1757  26  35  SC31  4  8  1689"  26  38  SC21  4  8 
1773  26  35  SC31  4  8  1688  3  7  SC31  4  8 
1946  26  35  SC31  4  8  1719  23  45  $1C2 (1,17)  4  8 
1796  2  44  SC31  4  8  1699"  2  44  SC30  4  8 
1763  3  14  SC2 (1,2)  4  8  1750  1  51  SC32  4  8 
1749"  1  35  SC31  5  3  2406  1  8  FC31  5  3 
Elements of known PV susceptibility  haplotypes are underlined. Patients 2006 and 2406 were not reported earlier; all others were reported (5, 6). 
* These haplotypes were incorrectly  guessed previously (5, 6) to be nonsusceptibility  haplotypes; see text. 
we found many individuals within families  of PV patients 
who were positive for low levels of the autoantibody. The 
study demonstrates that the inheritance of this autoantibody 
is consistent with dominant Mendelian genetics. It has been 
known from work done by others and by us that there are 
MHC class II genes that are associated  with PV (5,  6,  10, 
23-25), but the relationship of these alleles or extended haplo- 
types to the presence or absence of autoantibody was unknown. 
The distribution of homozygotes and heterozygotes for HLA- 
DR4 in Jewish patients with PV was consistent with domi- 
nant but not recessive inheritance (5,  6). 
Formal linkage analysis provides strong evidence for linkage 
between the MHC and the presence of PV antibody in rela- 
tives' families with odds of >109 to 1 for linkage (103 is evi- 
dence for linkage at p  =  0.05). Supposed recombinants were 
of two kinds, those in which a bearer of a suspected suscepti- 
bility haplotype or an arbitrarily assigned MHC haplotype 
failed  to have the antibody (11/17 of instances), and those 
in which an offspring who did not inherit that haplotype 
nevertheless had antibody (6/17). Although both situations 
could have arisen from recombination between the MHC and 
the putative immune response gene, other explanations are 
at least as likely.  The first kind of "recombinant" could be 
due to a failure of penetrance, or to lack of sensitivity of the 
autoantibody detection method. The unexpected presence of 
the antibody could be due to lack of specificity of the detec- 
tion assay (false positivity) or to inheritance of a suscepti- 
bility haplotype from the unaffected parent whose antibody 
response is impenetrant. Nonparenthood (for which we had 
no evidence) could also  confuse the picture. 
The current findings redefine the concept of penetrance, 
at least as it is applied to PV. In the sense of specifying the 
presence of antibody, penetrance of the MHC susceptibility 
gene is nearly complete even though penetrance for the dis- 
ease is much lower. Since multiple cases of PV in the same 
family are rare, neither the presence of the PV-associated MHC 
nor low levels of antibody suggest impending disease in an 
unaffected relative. 
There was a significant difference between the amounts 
or titers of the autoantibody (anticadherin) in the patients 
and the unaffected relatives.  Although PV is a rare disease, 
the  asymptomatic  presence  of low  levels  of nondisease- 
producing PV antibody could be several-fold more common, 
particularly in subjects who carry the specific MHC haplo- 
types known to be PV associated.  Our findings are consis- 
tent with these predictions. Of 103 control subjects enriched 
in specific susceptibility-type MHC haplotypes, only three 
individuals who were unrelated members of the nuclear fam- 
ilies of PV patients were found to carry low levels of PV anti- 
body. Other individuals with the same extended haplotype 
without disease, who were from other households, did not 
have detectable anticadherin  autoantibody. One positive elderly 
man without a specific susceptibility-type haplotype had my- 
asthenia gravis, known to be occasionally associated with PV 
422  MHC-linked  Antibody in Relatives of Pemphigus Patients antibody (22). The other two positive individuals were spouses 
of PV  patients  or  PV  antibody carriers  and both  carried 
susceptibility-type MHC haplotypes. This raises the ques- 
tion of a common household environmental factor such as 
a virus being involved in the production of low levels of PV 
antibody in MHC-susceptible persons.  We postulate that ei- 
ther a non-MHC gene or an environmental factor acts occa- 
sionally in the individual with low levels of pemphigus anti- 
body to increase production and this results in disease. 
Thus, our results suggest that the production of high levels 
of PV antibody, and thus the disease PV, is a two-step pro- 
cess. The first involves the MHC with or without an en- 
vironmental factor and leads to the presence of low levels of 
antibody. The second involves either an environmental factor 
and/or a non-MHC gene and results in high levels of the 
antibody. 
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